Challenges in Immuno-oncology (I-O): Future Use, Trial Design and Combination Strategies

Monday, July 2, 2018 Cancer News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, July 2, 2018 /PRNewswire/ -- Challenges in Immuno-oncology (I-O): Future Use, Trial Design and Combination StrategiesRead

the full report: https://www.reportlinker.com/p05467252 SummaryImmuno-oncology (I-O) is the treatment of cancer with immunotherapy, by using therapies to stimulate or suppress the body's own immune system to fight cancer. Several distinct
modalities of immunotherapy exist, including cytokines, vaccines, viruses, adoptive cell transfer, and checkpoint blockade using monoclonal antibodies.This report provides an assessment of the current status and future challenges of immuno-oncology across many indications. Overall, GlobalData expects innovative trial design and new combination drug approvals to drive immuno-oncology market growth.ScopeThis report combines primary research with a cross-specialty I-O KOL panel with in-house analyst expertise to provide an assessment of the marketplace.Components of the slide deck include -- Primary research with 20 US- and EU-based KOLs, from eight cancer specialties - breast, gastrointestinal, genitourinary, head & neck, lung, melanoma, sarcoma and hematology- Charts summarizing KOL's opinions and identifying response patterns- Call-outs of key information and details- KOL quotes- Insight from GlobalData's specialist oncology analystsReasons to buy- Develop and design your in-licensing and out-licensing strategies through a review of the potential of novel agents across tumor specialties by mechanism of action.- Develop business strategies by understanding the trends shaping and driving the global immuno-oncology market.- Drive revenues by understanding the key trends, innovative strategies and trial designs likely to impact the global immuno-oncology market in the future.- Organize your sales and marketing efforts by understanding the immunotherapy combination approaches across indications that present maximum opportunities for consolidations, investments, and strategic partnerships.Read the full report: https://www.reportlinker.com/p05467252 About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

Cision View original content:http://www.prnewswire.com/news-releases/challenges-in-immuno-oncology-i-o-future-use-trial-design-and-combination-strategies-300675467.html

SOURCE Reportlinker



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store